Biodexa Pharmaceuticals Plc Price & Performance (BDRX)

Biodexa Pharmaceuticals has called a General Meeting for May 2, 2025, in Cardiff to vote on subdividing each ordinary share, revising directors’ pay policy, and adopting new articles of association. The move aims to lower the par value of shares, facilitating future issuances, while leaving the total outstanding shares unchanged.12

Biodexa Pharmaceuticals’ stock closed at $1.43 on Thursday, down 2.05% for the day and 2.72% over the past ten days. The stock remains in a wide, downward trend with high volatility and low liquidity, prompting analysts to maintain a negative short-term outlook for BDRX shares.34

Biodexa Pharmaceuticals is advancing a Phase 3 trial for its eRapa drug targeting familial adenomatous polyposis, following FDA Fast Track and Orphan Drug designations. The company also named Dr. Gary A. Shangold as Chief Medical Officer, reinforcing its focus on clinical innovation and leadership as it targets diseases with unmet needs.25